Ataxia Telangiectasia Mutated Proteins
"Ataxia Telangiectasia Mutated Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of PROTEIN-SERINE-THREONINE KINASES which activate critical signaling cascades in double strand breaks, APOPTOSIS, and GENOTOXIC STRESS such as ionizing ultraviolet A light, thereby acting as a DNA damage sensor. These proteins play a role in a wide range of signaling mechanisms in cell cycle control.
| Descriptor ID |
D064007
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.097 D12.776.157.687.125 D12.776.660.720.125
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ataxia Telangiectasia Mutated Proteins".
Below are MeSH descriptors whose meaning is more specific than "Ataxia Telangiectasia Mutated Proteins".
This graph shows the total number of publications written about "Ataxia Telangiectasia Mutated Proteins" by people in this website by year, and whether "Ataxia Telangiectasia Mutated Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 0 | 4 | 4 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 2 | 0 | 2 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ataxia Telangiectasia Mutated Proteins" by people in Profiles.
-
Chromatin compartmentalization regulates the response to DNA damage. Nature. 2023 Nov; 623(7985):183-192.
-
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep; 7:e2300279.
-
Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023 03 20; 41(9):1703-1713.
-
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies. Curr Hematol Malig Rep. 2022 08; 17(4):94-104.
-
Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis. JAMA Oncol. 2022 04 01; 8(4):587-596.
-
DNA Double-strand Break Signaling Is a Therapeutic Target in Head and Neck Cancer. Anticancer Res. 2021 Nov; 41(11):5393-5403.
-
Topoisomerase 1 prevents replication stress at R-loop-enriched transcription termination sites. Nat Commun. 2020 08 07; 11(1):3940.
-
ATM mutation in a patient with thymoma-associated myasthenia gravis. Muscle Nerve. 2020 08; 62(2):E50-E52.
-
Pulmonary Granular Cell Tumors: A Study of 4 Cases Including a Malignant Phenotype. Am J Surg Pathol. 2019 10; 43(10):1397-1402.
-
Repair-independent functions of DNA-PKcs protect irradiated cells from mitotic slippage and accelerated senescence. J Cell Sci. 2019 07 01; 132(13).